Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
pubmed:
11
3
2024
medline:
11
3
2024
entrez:
11
3
2024
Statut:
epublish
Résumé
Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection from disease progression. Non-neutralizing antibodies cannot directly protect from infection but may recruit effector cells thus contribute to the clearance of infected cells. Also, they often bind conserved epitopes across multiple variants. We characterized 42 human mAbs from COVID-19 vaccinated individuals. Most of these antibodies exhibited no neutralizing activity
Identifiants
pubmed: 38464151
doi: 10.1101/2024.02.28.582613
pmc: PMC10925278
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI168631
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI172531
Pays : United States
Organisme : NIH HHS
ID : S10 OD026880
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR004419
Pays : United States
Organisme : NIH HHS
ID : S10 OD030463
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI168178
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIGMS NIH HHS
ID : U24 GM129539
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States
Déclaration de conflit d'intérêts
Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list Florian Krammer as co-inventor. Dr. Simon is also listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. Florian Krammer is co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. The Ellebedy laboratory has received funding under sponsored research agreements from Moderna, Emergent BioSolutions, and AbbVie. A.H.E. has received consulting and speaking fees from InBios International, Inc, Fimbrion Therapeutics, RGAX, Mubadala Investment Company, AstraZeneca, Moderna, Pfizer, GSK, Danaher, Third Rock Ventures, Goldman Sachs, and Morgan Stanley; is the founder of ImmuneBio Consulting and a recipient of royalties from licensing agreements with Abbvie and Leyden Laboratories B.V.
Références
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Front Immunol. 2022 Jan 14;12:808932
pubmed: 35095897
Nat Commun. 2017 Apr 10;8:15092
pubmed: 28393837
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679958
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Semin Immunopathol. 2023 Jul 12;:
pubmed: 37436465
Science. 2022 Aug 12;377(6607):735-742
pubmed: 35857703
PLoS One. 2023 Mar 30;18(3):e0282147
pubmed: 36996137
Front Immunol. 2019 Feb 28;10:332
pubmed: 30873178
Cell. 2014 Sep 11;158(6):1243-1253
pubmed: 25215485
Science. 1991 Dec 20;254(5039):1785-8
pubmed: 1837175
J Immunol. 1993 Jan 15;150(2):605-16
pubmed: 8419492
Crit Rev Immunol. 2010;30(1):47-52
pubmed: 20370619
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):20054-20062
pubmed: 31484758
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
J Biol Chem. 1994 Mar 25;269(12):8878-84
pubmed: 8132624
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Cell Mol Immunol. 2022 Mar;19(3):447-448
pubmed: 35043006
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Struct Mol Biol. 2015 Nov;22(11):833-4
pubmed: 26581513
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
mBio. 2024 Jan 16;15(1):e0225023
pubmed: 38112467
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Lancet Reg Health Eur. 2023 May 6;:100646
pubmed: 37363799
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
PLoS One. 2021 Dec 21;16(12):e0260954
pubmed: 34932587
Cell. 2020 Dec 10;183(6):1508-1519.e12
pubmed: 33207184
Nucleic Acids Res. 2016 Jul 8;44(W1):W474-8
pubmed: 27131379
J Exp Med. 1994 Sep 1;180(3):1165-70
pubmed: 8064233
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Vaccines (Basel). 2020 Dec 17;8(4):
pubmed: 33348607
EJNMMI Res. 2023 Sep 11;13(1):81
pubmed: 37697076
Exp Mol Med. 2022 Nov;54(11):1850-1861
pubmed: 36319752
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell. 2021 Jul 22;184(15):3936-3948.e10
pubmed: 34192529
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Nat Rev Nephrol. 2016 Jul;12(7):383-401
pubmed: 27211870
Nat Immunol. 2017 Nov 16;18(12):1288-1298
pubmed: 29144501
Cell Host Microbe. 2016 Jun 8;19(6):800-13
pubmed: 27281570
J Virol. 2017 Nov 30;91(24):
pubmed: 29046448
Nature. 2021 Sep;597(7874):103-108
pubmed: 34280951
Lancet Microbe. 2023 Aug;4(8):e569
pubmed: 37141905
Sci Transl Med. 2022 Jun 29;14(651):eabm3151
pubmed: 35767652
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Sci Immunol. 2023 Mar 17;8(81):eade0958
pubmed: 36701425
J Immunol. 2006 Sep 15;177(6):3848-56
pubmed: 16951347
J Biol Chem. 2017 Mar 3;292(9):3900-3908
pubmed: 28077575
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
J Immunol. 1991 Oct 15;147(8):2657-62
pubmed: 1833457
Immunol Rev. 2022 Sep;310(1):6-26
pubmed: 35661178
Sci Adv. 2021 Nov 26;7(48):eabj5629
pubmed: 34826237
Nature. 2007 Sep 6;449(7158):101-4
pubmed: 17805298
J Clin Invest. 2016 Feb;126(2):605-10
pubmed: 26731473
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
Mol Immunol. 2005 Feb;42(4):501-10
pubmed: 15607806
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Sci Rep. 2022 Sep 16;12(1):15612
pubmed: 36114224
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
Cell. 2021 Jun 24;184(13):3452-3466.e18
pubmed: 34139176
Front Immunol. 2019 Jun 07;10:1296
pubmed: 31231397
MAbs. 2017 Jul;9(5):767-773
pubmed: 28463043
BMJ Open. 2023 Dec 20;13(12):e076892
pubmed: 38128943
Sci Transl Med. 2022 Feb 09;14(631):eabj6824
pubmed: 34931886
mBio. 2021 Oct 26;12(5):e0190821
pubmed: 34544278
mBio. 2022 Apr 26;13(2):e0361721
pubmed: 35229637
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Nat Immunol. 2018 Nov;19(11):1169-1178
pubmed: 30333617
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7885):465-470
pubmed: 34547765
mBio. 2022 Jun 28;13(3):e0358021
pubmed: 35467422
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6181-6
pubmed: 22474370
Protein Sci. 2023 Nov;32(11):e4792
pubmed: 37774136
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Nat Protoc. 2020 Nov;15(11):3699-3715
pubmed: 32978602
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nat Commun. 2020 Nov 13;11(1):5752
pubmed: 33188207